State of availability of several hospital specialties

Two postponements available.peterspiro / iStock / Getty Images Plus / via Getty Images

EOn July 8 and 10, 2025, the National Agency for Medicines and Health Products (ANSM) reported new disruptions or updated the availability data of several specialties marketed in France [1]distributed exclusively at the hospital.

Bendamustine KIKMA, reported discount – State availability several hospital specialties

Bendamustine Kikma 2.5 mg/ml Powder for solution to be diluted for infusion (bendamustine)

Availability statement according to the ANSM – State availability several hospital specialties

Hizentra, subcutaneous immunoglobulins: end of transient recommendations for PIDC patients – State availability several hospital specialties

Hizentra 200 mg/ml Subcutaneous injection solution

Availability statement according to the ANSM

• Hizentra is no longer in supply tension [2]
• Another IGSC specialty will soon be available on the French market, for state availability several hospital specialties patients with polyradiculoned inflammatory demyelinating chronic (PIDC)
• Also, the recommendations so that these patients can be dealt with with other IGSC specialties are lifted

METHYLPREDNISOLONE VIATRIS 40 mg, indefinite

METHYLPREDNISOLONE VIATRIS 40 mg Powder for Injectable IM/IV solution (methylprednisolone hemisuccinate)

Availability statement according to the ANSM – State availability several hospital specialties

Zypadhera specialties: conducts to be held and measures to limit the impact

Zypadhera 210 mg, 300 mg and 405 mg powder and solvent for injectable suspension for prolonged liberation (Olanzapine)

Availability statement according to the ANSM

• Worsening tensions [3] due to temporary production difficulties (tensions reported in our article of June 26, 2025)
• Tensions relate mainly to 300 mg and 405 mg dosages. The 210 mg dosage should not be used as a substitution because:
  • The quantities are not sufficient
  • The dosage equivalences between the 210 state availability several hospital specialties mg. the 300 and 405 mg are not clearly established
• No longer initiate treatment to allow patients already treated to continue to access it
• Consider a relay:
  • from the injectable form to the oral form of olanzapine for patients in whom this is possible
  • Or a relay by another antipsychotic when an injectable form with prolonged action is necessary. But. taking into account the duration of action of the injectable form of Olanzapine – up to 6 to 8 months – the ANSM stresses that “ It is generally preferable to favor a relay by oral olanzapine rather than a change in molecule, especially if an injectable olanzapine return is envisaged later »
• Discount date: from September 2025

For health professionals

• In the event of an Olanzapine Injectable Olanzapine relay: ANSM recommends initiating a very low dose state availability several hospital specialties of oral olanzapine on the date initially provided for the following injection, with clinical surveillance, in particular during the first two months, to be adapted then according to the patient’s development (clinical response and tolerance) after stopping Zypadhera.

• In the event of an olanzapine relay injectable to another antipsychotic (when the use of an injectable antipsychotic for prolonged release is essential): the ANSM recommends first carrying out a relay to the oral form of the new antipsychotic to assess the tolerance of the patient and the effectiveness of the drug before prescribing the injectable shape of this antipsychotic. The relay terms are the same as before.

• After a change in treatment, doctors and patients should be particularly attentive to any unusable adverse effects or unusual symptoms.